Get started
Author

Yasuyuki Kaneta

Observed name: Kaneta, Yasuyuki
ORCID: 0000-0003-2799-2487
Observed ORCID: 0000-0003-2799-2487
OpenAlex ID: A5082322594
Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice
2002 · Yasuhiro Takeuchi, Sumiyo Watanabe, et al. · Journal of Biological Chemistry · 142
PDF
Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis.
2002 · Jun-ichi Okutsu, Tatsuhiko Tsunoda, et al. · PubMed · 78
Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray
2003 · Yasuyuki Kaneta, Yoshitoyo Kagami, et al. · International Journal of Oncology · 52
Prediction of Sensitivity to STI571 among Chronic Myeloid Leukemia Patients by Genome‐wide cDNA Microarray Analysis
2002 · Yasuyuki Kaneta, Yoshitoyo Kagami, et al. · Japanese Journal of Cancer Research · 52
Identification of Physiologically Active Substances as Novel Ligands for MRGPRD
2012 · Makiko Uno, Satoko Nishimura, et al. · BioMed Research International · 46
PDF
NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamics
2013 · Yasuyuki Kaneta, Axel Ullrich · Biochemical and Biophysical Research Communications · 32
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity
2019 · Toru Taniguchi, Hiroaki Inagaki, et al. · ACS Medicinal Chemistry Letters · 27
MRGD, a MAS-related G-protein Coupled Receptor, Promotes Tumorigenisis and Is Highly Expressed in Lung Cancer
2012 · Satoko Nishimura, Makiko Uno, et al. · PLoS ONE · 27
PDF
Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model
2022 · Akiko Toyota, Megumi Goto, et al. · Biochemical and Biophysical Research Communications · 17
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al. · Molecular Cancer Therapeutics · 8
Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor
2018 · Yasuyuki Kaneta, Takahiro Komatsu, et al. · Molecular Cancer Therapeutics · 3
Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581
2024 · Toru Taniguchi, Isao Yasumatsu, et al. · ACS Medicinal Chemistry Letters · 2
PDF
Supplementary Tables from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2025 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2025 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2025 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Tables from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al.
Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al.
Data from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
2023 · Kohei Takano, Yoichi Munehira, et al.
Validation Study on the Prediction of Response to Imatinib Mesylate in Chronic Myeloid Leukemia (CML) Patients by Genome-Wide cDNA Microarray Analysis.
2004 · Yoshitoyo Kagami, Toyomasa Katagiri, et al. · Blood
Gene expression profiling of normal human fibroblasts treated by ionizing radiation
2002 · Ishikawa, Kenichi, Sagara, Masashi, et al. · Institutional Repositories DataBase (IRDB)
Works count: 22
Citation count: 486
H-index: 9
I10-index: 9
Year
Topic
Type